Late-stage Product Development and Approvals by Biotechnology Companies After Initial Public Offering, 1997–2016
نویسندگان
چکیده
منابع مشابه
Financing Development Stage Biotechnology Companies: RMs vs
We examine reverse mergers (RMs) in the biotechnology industry and find that, when compared to initial public offerings (IPOs), RMs are smaller, have significantly lower market valuations relative to size, and generally invest less. We also find that RMs exhibit positive abnormal returns on the announcement date and throughout the first year after the RM event. In looking at liquidity measures,...
متن کاملInsurer Information, Insiders and Initial Public Offering
Reproduction partielle permise avec citation du document source, incluant la notice ©. Short sections may be quoted without explicit permission, if full credit, including © notice, is given to the source. CIRANO Le CIRANO est un organisme sans but lucratif constitué en vertu de la Loi des compagnies du Québec. Le financement de son infrastructure et de ses activités de recherche provient des co...
متن کاملThe Alternative to an Initial Public Offering
For over a year, the market for initial public offerings (IPO) for promising private companies has been slow. In 2007, there were just 234 IPOs, down from a decade high of 486 in 1999. As a result, private companies and their investors (including venture capital and private equity backed companies) have been left without a crucial exit strategy. More importantly, these private companies that mi...
متن کاملOwnership Concentration and Initial Public Offering Performance: Evidence from Thailand
This study examines the relation between ownership concentration and performance of initial public offerings (IPOs) in Thailand during 1989-1993. Ownership concentration plays a crucial role in emerging capital markets such as Thailand and can significantly affect IPO performance. Several testable hypotheses are constructed from the IPO literature to examine short-term and long-term IPO perform...
متن کاملThe initial public offering from a tripartite point of view
Existing literature on initial public offerings of a firm’s stock has taken into analysis only two parties of the issuer, the underwriter, the informed investor, either by neglecting one party for simplification or uniting it with another one as if they pursue the unique interests by forming a coalition. In point of fact, the issuer, the underwriter, the informed investors are separate entities...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Therapeutics
سال: 2021
ISSN: 0149-2918
DOI: 10.1016/j.clinthera.2020.11.012